Alvotech (ALVO) Income from Non-Controlling Interests (2024 - 2026)
Alvotech's (ALVO) quarterly Income from Non-Controlling Interests came in at $660.7 million in Q1 2026, down 66.82% quarter-over-quarter from $2.0 billion in Q4 2025.
Analysis
Alvotech (ALVO) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Income from Non-Controlling Interests for 3 consecutive years, with $660.7 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests changed N/A year-over-year to $660.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 billion (changed N/A YoY), and the FY2024 full-year result was -$3.0 million, changed N/A from the prior year.
- Income from Non-Controlling Interests fell to $660.7 million in Q1 2026 per ALVO's latest filing, from $2.0 billion in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $2.0 billion in Q4 2025 and bottomed at -$3.0 million in Q4 2024.
- Historically, Income from Non-Controlling Interests has averaged $661.5 million across 3 years, with a median of $328.9 million in 2024.
- The widest YoY moves for Income from Non-Controlling Interests: up 67142.63% in 2025, down 67142.63% in 2025.
- Over 3 years, Income from Non-Controlling Interests stood at -$3.0 million in 2024, then jumped by 67142.63% to $2.0 billion in 2025, then tumbled by 66.82% to $660.7 million in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $660.7 million, $2.0 billion, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.17 Bn | 18.28 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.88 Bn | 9.71 Bn | 396.53 Mn | -918,959.97 |
| 4 | Amneal Pharmaceuticals | 5.47 Bn | 5.34 Bn | 334.51 Mn | 11.95 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 494.50 Mn | 2.10 Bn | 2.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 994.21 Mn | 704.09 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 400.89 Mn | 359.65 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 660.69 Mn |
| Dec 31, 2025 | 1.99 Bn |
| Sep 30, 2025 | -2.97 Mn |
| Dec 31, 2024 | -2.97 Mn |